3 active not recruiting, 2 completed. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Recurrent Urethral Urothelial Carcinoma: new trials by email Literature Review of Recurrent Urethral Urothelial Carcinoma trials Research Report on Recurrent Urethral Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-07-31 |
| Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Erlotinib Hydrochloride - Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 34 | 2008-06-10 | 2020-09-10 |
Ureteral Neoplasms (5) · Urethral Neoplasms (5) · Urinary Bladder Neoplasms (5) · Carcinoma, Transitional Cell (3)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Ureteral Diseases (5) · Urethral Diseases (5) · Urinary Bladder Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Urologic Diseases (5) · Urologic Neoplasms (5) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3)
Specimen Handling (3) · Biopsy (2) · atezolizumab (2) · Contrast Media (1) · Erlotinib Hydrochloride (1) · Interleukin-7 (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · enfortumab vedotin (1) · erdafitinib (1) · eribulin (1) · relatlimab (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2)
United States (5) · Canada (1)
Anishka A D'Souza (1) · Arlene Siefker-Radtke (1) · Evan Y Yu (1) · Rohit Jain (1) · Sangeeta Goswami (1)
P30CA015704 (1), P30CA016672 (1), U01CA154967 (1), UM1CA186644 (1), UM1CA186717 (1)